Disease | collagen disease |
Phenotype | C0032285|pneumonia |
Sentences | 11 |
PubMedID- 22216165 | It has also been reported that administration of high dose ulinastatin 9×105 units/day resulted in clinical as well as radiological improvements of interstitial pneumonia in patients with connective tissue diseases [14], [15]. |
PubMedID- 25828844 | Methods: from 101 patients with severe r-ph collected by postal survey at the first stage, 70 patients with four major diseases (chronic obstructive pulmonary disease (copd), combined pulmonary fibrosis with emphysema (cpfe), interstitial pneumonia associated with connective tissue disease (ctd-ip), interstitial pneumonia (ip)) and normal pulmonary arterial wedge pressure were studied for clinical characteristics, treatment and prognosis. |
PubMedID- 24576910 | Efficacy of combined therapy with cyclosporin and low-dose prednisolone in interstitial pneumonia associated with connective tissue disease. |
PubMedID- 26543791 | Mean sicam-1 levels were 434 +/- 139 ng/ml for the stable phase of ipf, 645 +/- 247 ng/ml for early phase of acute exacerbation of ipf, 534 +/- 223 ng/ml for connective tissue disease-associated interstitial pneumonia, 221 +/- 42 for chronic obstructive pulmonary disease, and 150 +/- 32 ng/ml in healthy volunteers. |
PubMedID- 22466117 | Jiroveci pneumonia, in patients with connective tissue diseases. |
PubMedID- 22618987 | Diffuse interstitial pneumonia (ip) associated with collagen disease is a rare indication for lung transplantation. |
PubMedID- 22818583 | This article emphasizes interstitial pneumonia in association with connective tissue disease and the characteristics that differentiate this entity from idiopathic types. |
PubMedID- 25480740 | Bronchiolitis obliterans organizing pneumonia in patients with autoimmune rheumatic diseases. |
PubMedID- 21959291 | Primary prophylaxis for pneumocystis jirovecii pneumonia in patients with connective tissue diseases. |
PubMedID- 25708837 | Pneumocystis jirovecci pneumonia in connective tissue diseases: comparison with other immunocompromised patients. |
PubMedID- 23903809 | Although ae was first described in patients with ipf,1 it has also been reported in underlying diseases other than ipf, such as interstitial pneumonia associated with connective tissue disease,23 fibrotic non-specific interstitial pneumonia (nsip),23 hypersensitivity pneumonitis4 and asbestosis.5 this suggests that a variety of chronic fibrosing processes of the lung can present a potential risk for ae. |
Page: 1